Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 17 (7), 509-527

The Promise and Challenges of Immune Agonist Antibody Development in Cancer

Affiliations
Review

The Promise and Challenges of Immune Agonist Antibody Development in Cancer

Patrick A Mayes et al. Nat Rev Drug Discov.

Abstract

Immune cell functions are regulated by co-inhibitory and co-stimulatory receptors. The first two generations of cancer immunotherapy agents consist primarily of antagonist antibodies that block negative immune checkpoints, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte protein 4 (CTLA4). Looking ahead, there is substantial promise in targeting co-stimulatory receptors with agonist antibodies, and a growing number of these agents are making their way through various stages of development. This Review discusses the key considerations and potential pitfalls of immune agonist antibody design and development, their differentiating features from antagonist antibodies and the landscape of agonist antibodies in clinical development for cancer treatment.

Similar articles

See all similar articles

Cited by 18 articles

See all "Cited by" articles

References

    1. Cancer Cell. 2011 Jan 18;19(1):101-13 - PubMed
    1. Cytokine Growth Factor Rev. 2014 Aug;25(4):453-72 - PubMed
    1. Hybridoma. 1999 Oct;18(5):391-8 - PubMed
    1. Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a002436 - PubMed
    1. Blood. 2011 Dec 22;118(26):6772-82 - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback